Entering text into the input field will update the search result below

EC clears Imbruvica

Oct. 17, 2014 9:18 AM ETPharmacyclics, Inc. (PCYC) StockBy: Douglas W. House, SA News Editor1 Comment
  • The European Commission approves Pharmacyclics (NASDAQ:PCYC) and Janssen's (JNJ) Imbruvica (ibrutinib) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma or adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy or in first-line CLL patients in the presence of 17p deletion or TP53 mutation who are unsuitable for chemotherapy.
  • The FDA approved Imbuvica in July.

Recommended For You

Related Stocks

SymbolLast Price% Chg
PCYC--
Pharmacyclics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.